You are viewing archived content
Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the European Union Drugs Agency (EUDA).
Figure INF-13: Estimated HIV, HCV and HBV prevalence among injecting drug users – studies with national and sub-national coverage. Summary of all available data across EU Member States, candidate countries and Norway, 2000 to 2004
Notes:
HCV:
Countries with data available for HCV: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Germany, Estonia, Spain, Finland, Greece, Hungary, Ireland, Italy, Lithuania, Latvia, Malta, The Netherlands, Norway, Poland, Portugal, Romania, Slovenia, Slovakia, Turkey and United Kingdom.
Number of samples: 287
Total sample size: 408125
HIV:
Countries with data available for HIV: Austria, Belgium, Bulgaria, Czech Republic, Germany, Estonia, Denmark, Spain, Finland, France, Greece, Hungary, Ireland, Italy, Lithuania, Luxembourg, Latvia, Malta, The Netherlands, Norway, Poland, Portugal, Romania, Slovenia, Slovakia, Turkey and United Kingdom.
Number of samples: 433
Total sample size: 559592
HBV antibodies:
Countries with data available for HBV antibodies: Austria, Belgium, Bulgaria, Cyprus, Germany, Estonia, Spain, Ireland, Italy, Lithuania, Latvia, The Netherlands, Norway, Poland, Portugal, Slovenia, Slovakia and United Kingdom.
Number of samples: 200
Total sample size: 294277
HBV HBsAg:
Countries with data available for HBsAg: Belgium, Greece, Hungary, Ireland, Malta, The Netherlands, Poland, Portugal, Romania and Slovenia.
Number of samples: 106
Total sample size: 61805
See also 'General notes for interpreting data' on the Explanatory notes and help page.
Sources:
Reitox national focal points. See Table INF-8, Table INF-11, Table INF-14 and Table INF-15 for the original data.